Abstract: This article irons out the issue of recursive state estimation for mobile robot localization under a multiple description coding scheme. For the sake of optimizing the utilization of channel ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

The Eagles guitarist previewed his auction items at The Troubadour in Los Angeles on Monday, Dec. 8 Ilana Kaplan is a Staff Editor at PEOPLE. She has been working at PEOPLE since 2023. Her work has ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Since decoding the “waggle dance” in the 1940s, bees have been at the forefront of research into insect intellect. A new study shows that bees can be trained to understand the dot-dash behavior of ...

A new study shows that bumblebees can distinguish between long and short flashes of light, a skill previously seen only in humans and certain vertebrates. Credit: Shutterstock A study shows that ...

A new study is the first to show that an insect can differentiate between different durations of visual cues. In Morse code, a short duration flash or “dot” denotes a letter “E” and a long duration ...

It is well known that pictographic languages that use Hanzi, like Mandarin, are difficult to work with for computer input and output devices. After all, each character is a tiny picture that ...

In a first-of-its-kind study, scientists found that bumblebees can tell the difference between short and long light flashes, much like recognizing Morse code. The insects learned which signal led to a ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...